Literature DB >> 29501229

Mitochondria and Hypoxia: Metabolic Crosstalk in Cell-Fate Decisions.

David Bargiela1, Stephen P Burr1, Patrick F Chinnery2.   

Abstract

Alterations in mitochondrial metabolism influence cell differentiation and growth. This process is regulated by the activity of 2-oxoglutarate (2OG)-dependent dioxygenases (2OGDDs) - a diverse superfamily of oxygen-consuming enzymes - through modulation of the epigenetic landscape and transcriptional responses. Recent reports have described the role of mitochondrial metabolites in directing 2OGDD-driven cell-fate switches in stem cells (SCs), immune cells, and cancer cells. An understanding of the metabolic mechanisms underlying 2OGDD autoregulation is required for therapeutic targeting of this system. We propose a model dependent on oxygen and metabolite availability and discuss how this integrates 2OGDD metabolic signalling, the hypoxic transcriptional response, and fate-determining epigenetic changes.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2-oxoglutarate-dependent dioxygenases; HIF; hypoxia; metabolism; mitochondria

Mesh:

Year:  2018        PMID: 29501229     DOI: 10.1016/j.tem.2018.02.002

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  14 in total

Review 1.  Circles of Life: linking metabolic and epigenetic cycles to immunity.

Authors:  Chan-Wang Jerry Lio; Stanley Ching-Cheng Huang
Journal:  Immunology       Date:  2020-06-03       Impact factor: 7.397

2.  Metabolic Suppression of HIF-1α Contributes to Susceptibility of Ischemic Injury in Diabetic Hearts.

Authors:  Adam De Jesus; Hsiang-Chun Chang; Hossein Ardehali
Journal:  JACC Basic Transl Sci       Date:  2018-08-28

3.  Resveratrol alleviates hypoxia/reoxygenation injury‑induced mitochondrial oxidative stress in cardiomyocytes.

Authors:  Tao Li; Linlin Chen; Yiyan Yu; Binbin Yang; Pengyun Li; Xiao-Qiu Tan
Journal:  Mol Med Rep       Date:  2019-02-07       Impact factor: 2.952

4.  Role of HIF1α Regulatory Factors in Stem Cells.

Authors:  Hyun Jik Lee; Young Hyun Jung; Gee Euhn Choi; Jun Sung Kim; Chang Woo Chae; Ho Jae Han
Journal:  Int J Stem Cells       Date:  2019-03-30       Impact factor: 2.500

5.  Transport of Ca2+ and Ca2+-Dependent Permeability Transition in the Liver and Heart Mitochondria of Rats with Different Tolerance to Acute Hypoxia.

Authors:  Konstantin N Belosludtsev; Mikhail V Dubinin; Eugeny Yu Talanov; Vlada S Starinets; Kirill S Tenkov; Nadezhda M Zakharova; Natalia V Belosludtseva
Journal:  Biomolecules       Date:  2020-01-09

Review 6.  Tricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses.

Authors:  Inseok Choi; Hyewon Son; Jea-Hyun Baek
Journal:  Life (Basel)       Date:  2021-01-19

7.  Inhibiting Cardiac Mitochondrial Fatty Acid Oxidation Attenuates Myocardial Injury in a Rat Model of Cardiac Arrest.

Authors:  Peng Wang; Fan Zhang; Liming Pan; Yunke Tan; Fengqing Song; Qiulin Ge; Zitong Huang; Lan Yao
Journal:  Oxid Med Cell Longev       Date:  2021-03-01       Impact factor: 6.543

8.  O-cyclic phytosphingosine-1-phosphate stimulates HIF1α-dependent glycolytic reprogramming to enhance the therapeutic potential of mesenchymal stem cells.

Authors:  Hyun Jik Lee; Young Hyun Jung; Gee Euhn Choi; Jun Sung Kim; Chang Woo Chae; Jae Ryong Lim; Seo Yihl Kim; Joo Eun Lee; Min Chul Park; Jee Hyeon Yoon; Myeong Jun Choi; Kye-Seong Kim; Ho Jae Han
Journal:  Cell Death Dis       Date:  2019-08-05       Impact factor: 8.469

Review 9.  Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia.

Authors:  Sylwia Bartoszewska; James F Collawn
Journal:  Cell Mol Biol Lett       Date:  2020-03-13       Impact factor: 5.787

Review 10.  Autonomous glucose metabolic reprogramming of tumour cells under hypoxia: opportunities for targeted therapy.

Authors:  Mingyao Huang; Liang Yang; Xueqiang Peng; Shibo Wei; Qing Fan; Shuo Yang; Xinyu Li; Bowen Li; Hongyuan Jin; Bo Wu; Jingang Liu; Hangyu Li
Journal:  J Exp Clin Cancer Res       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.